Patient Awareness and Empowerment: Effective Strategy for Optimal Therapeutic Outcomes
Patient empowerment is the process through which people gain greater control over decisions and actions affecting their health.1
Encouraging patients to play a more active role in managing their health is important for improving clinical outcomes.1
How relevant is the content of this newsletter to you?
MAT-IN-2401070 v.1.0-7/24
leave-site-modal-text
You are now being redirected to a third-party website.
Sanofi does not endorse or approve the content, products, services or opinions on the third-party website. Sanofi shall not be responsible or in any way liable for any injury or damage to any persons in view of any reliance placed on or action taken basis of the information on the third party website or any errors, omissions or inaccuracies and/or incompleteness of the information on the third party website.
Right answer: Both A and B. As per Diabetic & Ramadan guidelines, T2DM patients can safely continue glargine U-100 once daily at a reduced dose of 15 - 30% at Iftar1,2. Insulin glargine U-100 is safe to be used during Ramadan with no significant increase in hypoglycaemia3. One-on-one dietary educational session can also reduce the number of adverse events of fasting1.
